| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Pict-1 stabilizes PTEN, regulates the MDM2-p53 pathway. High expression levels of Pict1 are associated poor prognosis of several cancers with wild-type TP53. Solar Keratosis develops squamous cell carcinoma(SCC) in skin, so we studied clinical prognosis of solar keratosis in human with topical imiquimod application. Some clinical parameters, e.g. solitary, multiple, CR, PD, SCC progression were investigated. Immunohistochemical expression of Pict-1 and p53(WT, mutant) revealed imiquimod effective solar keratosis(CR) with higher cytoplasmic and nuclear Pict-1. It decreases imiquimod resistant solar keratosis(PD) and SCC. Weak p53 expression with strong cytoplasmic Pict1 in CR case, and no p53 expression in PD case. Paradoxically, strong p53 expression of SCC, suggesting more mutant p53 in SCC. These result suggests some mechanisms of UV carcinogenesis prevention in epidermis might regulate Pict-1 and p53 expression.
|
